Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05219734 · ClinicalTrials.gov registry record
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
A clinical trial of Cancer and Non-Small Cell Lung Cancer, sponsored by Invitae Corporation.
- Active
- Registry status
- 400
- Enrollment target
- 2
- Study locations
NCT05219734: Active study of Cancer and Non-Small Cell Lung Cancer, sponsored by Invitae Corporation.
NCT05219734 is a study of Cancer and Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Invitae Corporation. The registered enrollment target is 400 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05219734, a study of Cancer and Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Invitae Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study recruits patient with solid tumor types for sample collection and monitoring. Participants will provide blood and archival tissue samples in order to create a Personalized Cancer Monitoring (PCM) assay. This assay will be used to detect circulating tumor DNA (ctDNA) levels in the blood over time and hopefully contribute to improvements in residual disease detection methods for future patients. Results from this assay will be provided to participants and providers but providers are not asked to change patient care based on this information.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Personalized Cancer Monitoring (PCM)
Study Locations (2)
Indiana
- Columbus Regional Health - Columbus
North Carolina
- Onslow Radiation - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2021-11-29 |
| Est. Completion | 2026-12 |
What the registry record for NCT05219734 still lists
NCT05219734 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (89% lower).
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Personalized Cancer Monitoring (PCM) is the first listed.
NCT05219734 reports a single indexed study location in Indiana, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05219734 about?
NCT05219734 is a clinical study titled "MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment". This study recruits patient with solid tumor types for sample collection and monitoring. Participants will provide blood and archival tissue samples in order to create a Personalized Cancer Monitoring (PCM) assay. This assay will be used to detect circulating tumor DNA (ctDNA) levels in the blood ov...
What is the current status of trial NCT05219734?
This trial is currently active not recruiting. The enrollment target is 400 participants. The study started on 2021-11-29. Estimated completion is 2026-12.
What conditions does trial NCT05219734 study?
This clinical trial studies the following conditions: Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Bladder Cancer.
What interventions are being tested in trial NCT05219734?
The interventions under investigation include: Personalized Cancer Monitoring (PCM) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05219734?
This trial is sponsored by Invitae Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05219734 being conducted?
This trial has 2 study locations across Indiana, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05219734's enrollment target sits among peer trials
400 148th of 615 higher than 464 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI